The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice.
The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice.
复制标题
DOI：
10.1093/jn/138.9.1677
复制
发表时间：
2008-09
期刊：
影响因子：
--
通讯作者：
Yang CS
中科院分区：
文献类型：
--
作者：
Bose M;Lambert JD;Ju J;Reuhl KR;Shapses SA;Yang CS
在这项研究中，我们调查了主要的绿色茶多酚，（-）-表没食子儿茶素-3-没食子酸酯（EGCG），对高脂肪诱导的肥胖症，代谢综合征的症状，和脂肪肝小鼠的影响。在喂食高脂饮食（60%能量为脂肪）的小鼠中，与未接受EGCG治疗的小鼠相比，补充饮食EGCG治疗（3.2 g/kg饮食）16周降低了体重（BW）增加、体脂百分比和内脏脂肪重量（P < 0.05）。高脂组体重下降与粪便脂质增加有关（r2 = 0.521; P < 0.05）。EGCG治疗降低了高脂喂养小鼠的胰岛素抵抗、血浆胆固醇和单核细胞趋化蛋白浓度（P < 0.05）。EGCG治疗还降低了高脂喂养小鼠的肝脏重量、肝脏甘油三酯和血浆丙氨酸氨基转移酶浓度（P < 0.05）。肝脏样本的组织学分析显示，与未接受EGCG治疗的高脂饮食喂养的小鼠相比，接受EGCG治疗的小鼠肝细胞中的脂质积累减少。在另一项实验中，接受短期EGCG治疗（3.2g/kg饮食，4周）的3月龄高脂诱导的肥胖小鼠与高脂喂养的对照小鼠相比，肠系膜脂肪重量和血糖降低（P < 0.05）。我们的研究结果表明，长期的EGCG治疗减弱了肥胖，代谢综合征相关症状和脂肪肝的发展。短期EGCG治疗似乎可以逆转肥胖小鼠中预先存在的高脂肪诱导的代谢病变。这些作用可能是通过减少脂质吸收、减少炎症和其他机制介导的。
In this study, we investigated the effects of the major green tea polyphenol, (−)-epigallocatechin-3-gallate (EGCG), on high-fat–induced obesity, symptoms of the metabolic syndrome, and fatty liver in mice. In mice fed a high-fat diet (60% energy as fat), supplementation with dietary EGCG treatment (3.2 g/kg diet) for 16 wk reduced body weight (BW) gain, percent body fat, and visceral fat weight (P < 0.05) compared with mice without EGCG treatment. The BW decrease was associated with increased fecal lipids in the high-fat–fed groups (r2 = 0.521; P < 0.05). EGCG treatment attenuated insulin resistance, plasma cholesterol, and monocyte chemoattractant protein concentrations in high-fat–fed mice (P < 0.05). EGCG treatment also decreased liver weight, liver triglycerides, and plasma alanine aminotransferase concentrations in high-fat–fed mice (P < 0.05). Histological analyses of liver samples revealed decreased lipid accumulation in hepatocytes in mice treated with EGCG compared with high-fat diet-fed mice without EGCG treatment. In another experiment, 3-mo-old high-fat–induced obese mice receiving short-term EGCG treatment (3.2 g/kg diet, 4 wk) had decreased mesenteric fat weight and blood glucose compared with high-fat–fed control mice (P < 0.05). Our results indicate that long-term EGCG treatment attenuated the development of obesity, symptoms associated with the metabolic syndrome, and fatty liver. Short-term EGCG treatment appeared to reverse preexisting high-fat–induced metabolic pathologies in obese mice. These effects may be mediated by decreased lipid absorption, decreased inflammation, and other mechanisms.
登录
查看更多内容
影响因子：
4.8
作者：
Waltner-Law, ME;Wang, XHL;Granner, DK
通讯作者：
Granner, DK
影响因子：
4.9
作者：
Murase, T;Nagasawa, A;Tokimitsu, I
通讯作者：
Tokimitsu, I
影响因子：
2.7
作者：
Koyama, Y;Abe, K;Isemura, M
通讯作者：
Isemura, M
影响因子：
7.7
作者：
Morino, Katsutaro;Petersen, Kitt Falk;Shulman, Gerald I.
通讯作者：
Shulman, Gerald I.
影响因子：
16.2
作者：
Hosoda, K;Wang, MF;Yamamoto, S
通讯作者：
Yamamoto, S